Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2

Brian Khong1, Benjamin O. Lawson2, Junjie Ma3, Cheryl McGovern4, Joan K. Van Atta4, Abhijit Ray4 and Hung T. Khong5*

Abstract

Background: Rigors are a significant adverse event during interleukin-2 (IL-2) therapy for metastatic melanoma and renal cell carcinoma. Meperidine has been a mainstay for rigor prophylaxis but there is a paucity of data regarding possible alternatives.

Methods: Ninety one patients receiving IL-2 therapy for metastatic renal cell carcinoma and melanoma at Huntsman Cancer Institute (HCI), Utah from May 2009 to October 2016 were retrospectively evaluated for rigor prophylaxis. Forty two patients received meperidine and 49 received tramadol. Rigors were tabulated using the proxy of number of doses of as needed (PRN) rigor medications and normalized by IL-2 doses. Other outcomes of fever, hypotension, and renal insufficiency were noted on a binary scale and normalized by cycles. Statistical analysis was performed utilizing univariate and multivariate negative binomial models.

Results: Ninety one patients were identified with metastatic melanoma or RCC who received high dose IL-2 therapy. Forty two received meperidine and 49 received tramadol prophylaxis for rigors. Univariate negative binomial analysis shows incidence rate ratios (IRR): fever 0.41 (95% CI 0.28–0.62, p-value < 0.001), hypotension 1.7 (95% CI 1.11–2.61, p-value 0.015), renal insufficiency 0.58 (95% CI 0.35–0.98, p-value 0.041), rigors per all PRN meds 1.01 (95% CI 0.79–1.28, p-value 0.964), and rigors via opioid PRN meds 0.85 (95% CI 0.67–1.07, p-value 0.168). Multivariate negative binomial analysis shows IRR: fever 0.59 (95% CI 0.28–1.24, p-value 0.163), hypotension 0.93 (95% CI 0.43–2.03, p-value 0.864), renal insufficiency 1.1 (95% CI 0.52–2.32, p-value 0.807), rigors per all PRN meds 0.92 (95% CI 0.67–1.26, p-value 0.604), and rigors via opioid PRN 0.9 (95% CI 0.65–1.26, p-value 0.554).

Conclusion: Univariate models indicated meperidine pre-treatment was associated with significantly lower rates of fever and renal insufficiency whereas tramadol was associated with significantly lower rate of hypotension. However, when controlled for demographics and other treatment differences, these differences were no longer significant.

Keywords: High dose interleukin-2, Rigor prophylaxis, Melanoma, Renal cell carcinoma, Tramadol, Meperidine
Meperidine is predominantly a endothelial-cell antigens [9]. This in turn results in capillary tion products; neutrophil act ivation; and activation of and other interleukins; generation of complement-activa tion products; neutrophil activation; and activation of endothelial-cell antigens [9]. This in turn results in capillary leak syndrome-associated hypovolemia causing renal insufﬁciency secondary to pre-renal azotemia [9]. The release of cytokines after IL2 administration has also been implicated as the cause of flu-like symptoms, such as fevers, chills, my- algias, and arthralgias [9].

Chills, fever, and malaise are among the most common and predictable adverse events associated with HD IL2 [4]. Typically, chills develop within 1 to 2 h of the first or second dose and are treated with repeated doses of meperidine and warm blankets [9]. Fever, which usually develops within 2 to 4 h of administration of the first or second dose and may reach 40.5 C and is usually treated with anti-pyretics such as acetaminophen as well as addition of non-steroidal anti-inflammatory drug (NSAID), indomethacin, which has also been advocated [9, 10]. Renal toxicity associated with high-dose IL2 is typical of prerenal azotemia and is commonly a result of hypotension, decreased intravascular volume, and/or impaired cardiac function [9]. Renal toxicity is most effectively managed by administering fluid boluses at the onset of oliguria, with a relative limit on the total volume of 1 to 1.5 L/d above maintenance needs [9].

Meperidine has been the mainstay for rigor prophy laxis [11]. Meperidine is predominately a µ-receptor agonist and acts principally on the central nervous system [12]. Meperidine has been shown to be effective in eliminating post HD IL2 shivering or rigors and even considered the gold standard for the treatment of shivering [13]. It has seen extensive use for decades with the first mention in the 1980s for amphotericin chills [14].

However, rigors can persist and remain severe despite meperidine prophylaxis. Tramadol has been used as an alternative at the University of Utah. Tramadol acts similarly as a µ-opioid receptor agonist albeit more weakly with a longer half-life and has additional mechanistic effects such as partial inhibition of nor epinephrine and serotonin uptake [12]. Prior studies in anesthesiology analyzing the treatment of post-opera tive shivers [15, 16], spinal anesthetic shivers [17], and post-epidural shivers [18] have shown at least compar able efficacy of tramadol to meperidine with some studies finding superiority [15] or fewer side effects [18]. Meta-analyses of general shiver treatment have shown comparable effects between the two medications in critical care setting [12].

Methods
This was a retrospective cohort, chart review study performed at the Division of Oncology at Huntsman Cancer Institute of the University of Utah. The protocol was approved by the University of Utah Institutional Review Board who also formally waived ethics approval and consent. The study analyzed patients with metastatic renal cell carcinoma or metastatic melanoma receiving HD IL2 treatment with rigor premedication from September 2008 to December 2016. Demographic data, medical history, and treatment records were reviewed including data on age, gender, race, previous treatment, disease states and diagnoses, dates of HD IL2 treatment, and treatment adverse effects. Initial review identified 148 patients received IL2, of which 137 received HD IL2 treatment. The study population was parsed further to 91, removing those who did not receive sufﬁcient opioid prophylaxis or missed sufﬁcient clinical documentation. For rigor premedication, 42 patients received meperidine and 49 received tramadol.

Patients undergoing HD IL2 therapy underwent a maximum of 4 courses, each constituting two 1-week-long cy cles of IL2 dosing in the Intermediate Care Unit. For our study, we analyzed up to the first 4 cycles with actual number of doses and cycles completed dependent on tox icities and lack of disease progression. Patients received multiple premedications with each IL2 dose which included rigor prophylaxis in the form of meperidine or tramadol with variable adjuncts such as diphenhydramine, lorazepam, or morphine. As needed (PRN) medications used to treat rigor episodes included meperidine, mor phine, hydromorphone, diphenhydramine, and lorazepam.

Pertinent adverse effect outcomes were rigors, fever, hypotension, and renal insufﬁciency. Rigor severity and frequency were recorded by proxy; tabulating total amount of as needed medication to resolve rigor ep iso des per cycle. Each dose of the as needed medications was given a score of one, summed, and then normalized by the number of IL2 doses. High fever was noted if there were two or more episodes of fever > = 101 F occurring at least twice within the hour of onset. Severe hypotension was noted if SBP < 90 that required pressors. Significant renal injury was noted if serum creatinine was 1.8 mg/dL or higher or oliguric at less than 10 ml/hr. within a 12 h period. Except for rigors, these were graded on a binary scale then normalized by num ber of cycles.

Statistical signiﬁcance for all outcomes was determined via univariate regression analysis and then repeated with multivariate regression analysis to control for demograph ics and other possible confounding factors. Confounds
controlled in multivariate regression analysis included age at IL2 inception, IL2 doses, race, gender, previous treatment, malignancy type, and additional tramadol therapy given at physician’s discretion. Probability < 0.05 was considered significant.

Results
Enrollment and base-line characteristics of the patients
Between May 2009 and October 2016, 91 patients who were pre-treated with either meperidine or tramadol prior to HD IL2 were identified. The patients in the two groups in the primary analysis had similar baseline characteristics (Table 1 and Table 2).

Meperidine was given to 42 of the 91 patients with an average IL2 dose of 18.14 which was similar to those, average IL2 dose of 18.02, who received tramadol (p-value 0.940).

Tramadol was given to 49 of the 91 patients and of those 49 patients, 63% were diagnosed with Renal Cell Carcinoma and 37% were diagnosed with Melanoma. Whereas, 80% of the 42 patients that received meperidine were diagnosed with renal cell carcinoma and 20% were diagnosed with melanoma.

More patients in the meperidine group received previous treatment compared to patients in group 2 (35% vs 17%, p-value 0.052).

Furthermore, 24% patients that were pretreated with meperidine, actually received tramadol at some point during their treatment of high dose IL2 therapy (Table 2).

Outcomes
Without controlling for demographics, patients pre-treated with meperidine demonstrated less incidence of post-IL2 fever and renal insufficiency (IRR 0.41, 95% CI 0.28–0.62, p-value < 0.001 and IRR 0.58, 95% CI 0.35–0.98, p-value = 0.041). On the contrary, pre-treatment with tramadol was found to be superior to preventing hypotension (IRR 1.70, 95% CI 1.11–2.61, p-value = 0.015). Rigor prophylaxis was equivocal (Table 3).

Multivariate analysis showed different associations, and with control for confounds, the differences between the two groups were no longer significant. Patients who underwent IL2 therapy and pre-treated with meperidine had a lower rate of fever compared to those who were pre-treated with tramadol (IRR 0.59, 95% CI 0.28–1.24, p-value = 0.163).

Discussion
This is the first retrospective analysis examining alternatives to meperidine in HD IL2 patients for rigor prophylaxis as well as control of other adverse effects. IL2 therapy is associated with multiple adverse effects including rigor, fever, capillary leak, hypotension, and renal insufficiency due to its cytokine cascade [9]. While meperidine became the mainstay decades ago [9], there is a paucity of data regarding alternatives especially given

Table 1 Baseline characteristics with averages

| Group | Meperidine (N = 42) | Tramadol (N = 49) |
|-------|---------------------|-------------------|
| Age at IL2 | Mean: 51.52, SD: 9.25 | Mean: 53.90, SD: 9.04 |
| IL2 dose | Mean: 18.14, SD: 8.24 | Mean: 18.02, SD: 7.34 |

aGroup 1 includes patients who were pretreated with meperidine
bGroup 2 included those who were pretreated with tramadol

Table 2 Baseline characteristics with number of patients

| Group | Meperidine (N = 42) | Tramadol (N = 49) |
|-------|---------------------|-------------------|
| Race | N pts | % | N pts | % |
| White | 43 | 88% | 36 | 86% |
| Hispanic | 3 | 6% | 4 | 10% |
| American Indian | 3 | 6% | 0 | 0% |
| Unknown | 0 | 0% | 2 | 5% |
| Gender | | | | |
| Female | 14 | 29% | 17 | 40% |
| Male | 35 | 71% | 25 | 60% |
| Previous treatment | 17 | 35% | 7 | 17% |
| Malignancy | | | | |
| Renal Cell Carcinoma | 39 | 80% | 26 | 63% |
| Melanoma | 10 | 20% | 15 | 37% |
| Tramadol | 10 | 24% | 49 | 100% |

aGroup 1 includes patients who were pretreated with meperidine
bGroup 2 included those who were pretreated with tramadol

Table 3 Results of univariate negative binomial models

| Effect | IRR | 95% CI Upper | 95% CI Lower | p-value |
|--------|-----|--------------|--------------|---------|
| Fever | 0.41 | 0.28 | 0.62 | < 0.001 |
| Hypotension | 1.70 | 1.11 | 2.61 | 0.015 |
| Renal insufficiency | 0.58 | 0.35 | 0.98 | 0.041 |
| Rigors via all PRN meds | 1.01 | 0.79 | 1.28 | 0.964 |
| Rigors via opioid PRN med | 0.85 | 0.67 | 1.07 | 0.168 |

aIncidence Rate ratio
bRigor severity/frequency tabulated via proxy PRN medication of opioids, benzodiazepines, and antihistamines

Khong et al. BMC Cancer (2018) 18:1007 Page 3 of 5
that meperidine is renally excreted with the context of possible renal insufficiency associated with IL2 therapy. At the University of Utah, some providers had begun to supplant meperidine with tramadol thus prompting our investigation to possible differences. Tramadol, while mechanistically similar especially in metabolism and excretion, had been utilized with anecdotal superiority at Huntsman Cancer Institute possibly attributed to its longer half-life.

We examined 91 patients subdivided into two groups based on the primary rigor prophylaxis received. The scope was limited to meperidine and tramadol. Given that notation of rigor severity and frequency varied highly from patient to patient especially between different providers, as needed medications used afterwards to control rigors were tabulated as a suitable proxy for rigor severity/frequency. Because rigor treatment was highly variable, treatments ranged from opioids only to those who included diphenhydramine and lorazepam. Due to this heterogeneity, two data sets were parsed and analyzed separately with one set representing rigor proxy as opioid use only and another set with rigor treatment including opioids, benzodiazepines, and antihistamines. Other significant adverse effects noted above were observed for potential differences as well between the two groups.

Univariate analysis showed significantly lower rates of fever, and renal insufficiency in the meperidine group albeit with higher hypotension rates. Adjusting for age, dosage, race, gender, previous treatment, disease, and additional tramadol use obliterated these significant differences, showing only equivocation. These results imply tramadol would be a potentially reasonable alternative to meperidine for rigor prophylaxis.

Limitations
The study had several limitations, especially in its scope, heterogeneity of care, and the quality of the data. As multiple physicians and nurse practitioners supervised the care of the IL2 patients, treatment regimens and accuracy of recordkeeping varied highly. Rigors treatment between teams varied in terms of pre-medication and as needed medications. Differences included initial pre-medication choice, timing and frequency of premedication transitions, dosage sizes, and choice of as needed medication for particular rigor episodes. Treatment teams had distinct preferences, for example starting patients with meperidine pre-medication then switching to tramadol at later doses within cycles once rigors proved severe.

Records disparities were evident as well especially between clinical notes and medication records. Rigors noted in notes often did not match amounts of PRN medications actually ordered and administered. In some cases, notes mentioned multiple or severe rigors requiring multiple medications to resolve yet medication records showed few to no PRN medication for rigor resolution. This held true especially for records prior to late 2011. Given the disparity, the medication record was assumed to be more accurate.

Scoring for rigors via as needed medications was tabulated with equal scoring ascribed to each type regardless of narcotic type, dose size, and other PRN-drugs such as benzodiazepines and antihistamines. Dosage sizes of both pre-medications and as needed medications were not tabulated; only frequency was recorded irrespective of size. Likely such details of dose normalization and differentiation of rigor treatment medications would contribute to improved analysis of rigor control and affect our results. Additionally, given time restrictions, data on the other adverse effects of fever, hypotension, and renal insufficiency was tabulated in a simplified manner as noted above. This binary tabulation limits the detail by which we analyzed their severity and frequency.

Table 4 Results of multivariate negative binomial models

|                | IRR  | 95% CI Upper | 95% CI Lower | p-value |
|----------------|------|--------------|--------------|---------|
| Fever          | 0.59 | 0.28         | 1.24         | 0.163   |
| Hypotension    | 0.93 | 0.43         | 2.03         | 0.864   |
| Renal insufficiency | 1.10 | 0.52         | 2.32         | 0.807   |
| Rigors via all PRN med | 0.92 | 0.67         | 1.26         | 0.604   |
| Rigors via opioid PRN med | 0.90 | 0.65         | 1.26         | 0.554   |

*Adjusted for age at IL2, IL2 dose, race, gender, previous treatment, malignancy, and additional tramadol
*Incidence Rate ratio
*Rigor severity/frequency tabulated via proxy PRN medication of opioids, benzodiazepines, and antihistamines
*Rigors severity/frequency tabulated via proxy PRN opioid medications only

Conclusions
Tramadol appears to be a reasonable alternative to meperidine for rigor prophylaxis. Given the nonsignificant differences in adverse events of meperidine coupled with its long track record in this area, however, it may be beneficial to continue meperidine use. Further research is warranted to clearly observe the differences between the two especially in light of the limitations highlighted above. While severe rigors are rarely a dose limiting toxicity in our practice, proper management improves patient quality of life and remains an integral part of patient care.

Abbreviations
CI: confidence interval; HCI: Huntsman Cancer Institute; HD IL2: high dose interleukin-2; IL-2: Interleukin-2; IRR: incidence rate ratio; NCCN: National Comprehensive Cancer Network; NSAID: non-steroidal anti-inflammatory drug; PRN: as needed; RCC: renal cell carcinoma; SBP: systolic blood pressure

Availability of data and materials
The data that support the findings of this study are available from Huntsman Cancer Institute at University of Utah but restrictions apply to the availability of these data. They were accessed under license for the current study and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Huntsman Cancer Institute.
Authors’ contributions
Authors BK, BL, JM, and HK participated in the study design, data collection, analysis, drafting, and approval of the final manuscript. Authors CM, JA, and AR participated in study design and data collection.

Ethics approval and consent to participate
Ethics approval and consent were formally waived by the University of Utah Institutional Review Board (ethics committee).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Adventist Health White Memorial, 1720 East Cesar E Chavez Avenue, Los Angeles, CA 90033, USA. 2Honor Health Medical Center, 9003 E Shea Blvd, Scottsdale, AZ 85260, USA. 3Department of Pharmacotherapy, University of Utah, 30 S 2000 E, Salt Lake City, UT 84112, USA. 4Huntsman Cancer Institute, University of Utah, 2000 Cir of Hope Dr, Salt Lake City, UT 84103, USA. 5Department of Breast Oncology, Moffitt Cancer Center, 10920 McKinley Dr, Tampa, FL 33612, USA.

Received: 29 September 2017 Accepted: 12 September 2018

Published online: 20 October 2018

References
1. US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. 2010–2014. https://seer.cancer.gov/csr/1975_2014/results_single/sect_a_table03_2pgs.pdf Accessed 18 Apr 2017.
2. National Comprehensive Cancer Network. Melanoma. (Version 1.2017) https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf Accessed 22 Apr 2017.
3. National Comprehensive Cancer Network. Kidney Cancer. In: Version 2; 2017. https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf Accessed 22 Apr 2017.
4. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2: Interventions (table 3). Oncology. 2002;13:14.
5. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Szolm M, Atkins MB, Dutcher JP, Micetic K, Weiss GR. Randomized phase II trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J of Clin Onc. 1993;11(10):1969–77.
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Szolm M, Parkinson D, Hawkins M, Paradise C. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J of Clin Onc. 1999;17(7):2105.
7. Fyfe G, Fisher RI, Rosenberg SA, Szolm M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J of Clin Onc. 1995;13(3):688–96.
8. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83(6):797–805.
9. Schwartzentruber DJ. Interleukin-2: Clinical applications. Principles of administration and management of side effects. Principles and practice of the biologic therapy of Cancer. Philadelphia, PA: Lippin Wil & Wil. 2000;32–50.
10. Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mir J. Cytokine working group. Kidney cancer: the cytokine working group experience (1986–2000). Med Onc. 2001;18(3):209–19.
11. Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarini AA, Lowder JN, Atkins MB. High dose interleukin-2 (Aldesleukin)-expert consensus on best management practices-2014. J for ImmunoTherapy of Cancer. 2014;2(1):26.
12. Park SM, Mangat HS, Berger K, Rosengart AJ. Efficacy spectrum of antishivering medications: meta-analysis of randomized controlled trials. Crit Care Med. 2012;40(11):3070–82.
13. Dhimar AA, Patel MG, Swadil VN. Tramadol for control of shivering (comparison with pethidine). Indian J of Anaes. 2007;51(1):28.
14. Burks UC, Asiner J, Forrer CL, Wernik PH. Meperidine for the treatment of shaking chills and fever. Archiv of int med. 1980;140(4):483–4.
15. Bhatnagar S, Saxena A, Kannan TR, Punj J. Tramadol for postoperative shivering: a double-blind comparison with pethidine. Anes and int care. 2001;29(2):149.
16. Mohta M, Kumar N, Tyagi A, Sethi AK, Agarwal D, Singh M. Tramadol for prevention of postanaesthetic shivering: a randomised double-blind comparison with pethidine. Anes. 2009;64(2):141–6.
17. Witte J, Delooft T, Veylders J, Houmans PR. Tramadol in the treatment of postanaesthetic shivering. Acta Anaesthesiol Scand. 1997;41(4):506–10.
18. Tsai YC, Chu KS. A comparison of tramadol, amtripyline, and meperidine for postepidural anesthetic shivering in parturients. Anesth Analg. 2001;93(5):1288–92.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions